Currently Enrolling Clinical Trials
Jennerex is currently recruiting for the following studies:
Liver Cancer
TRAVERSE: A Phase 2b Randomized Trial of Pexa-Vec (JX-594) Plus Best Supportive Care Versus Best Supportive Care in Patients With Advanced Hepatocellular Carcinoma Who Have Failed Sorafenib Treatment
To learn more please visit: www.traversetrial.com
Clinicaltrials.gov identifier: NCT01387555
Colorectal Cancer
A Phase 1b Dose Escalation Study of Pexa-Vec (JX-594) Administered Every Two Weeks Intravenous Infusion in Patients With Metastatic, Refractory Colorectal Carcinoma
Clinicaltrials.gov identifier: NCT01380600
A Phase 1/2a Dose-escalation Study of Pexa-Vec (JX-594) Administered by Multiple Intravenous (IV) Infusions Followed by Intratumoral (IT) Boosts Alone and in Combination with Irinotecan in Patients with Metastatic, Refractory Colorectal Carcinoma.
Clinicaltrials.gov identifier: NCT01394939
Kidney Cancer
A Single-Arm Phase 2 Study of Pexa-Vec (JX-594) Administered by Weekly Intravenous (IV) Infusions in Patients with Metastatic, Refractory Renal Cell Carcinoma (RCC)*
*Investigator Initiated study
Ovarian Cancer*
A Single-Arm, Open-Label Phase 2 Study of Pexa-Vec (JX-594) Administered by 5 Weekly Intravenous (IV) Infusions in Patients with Peritoneal Carcinomatosis of Ovarian Cancer Origin*
*Investigator Initiated study
Patients, Advocates and Medical Professionals:
For more information:
http://www.clinicaltrials.gov
